- Ng, Dianna;
- Goldgof, Gregory;
- Shy, Brian;
- Levine, Andrew;
- Balcerek, Joanna;
- Bapat, Sagar;
- Prostko, John;
- Rodgers, Mary;
- Coller, Kelly;
- Pearce, Sandra;
- Franz, Sergej;
- Du, Li;
- Stone, Mars;
- Pillai, Satish;
- Sotomayor-Gonzalez, Alicia;
- Servellita, Venice;
- Sanchez-San Martin, Claudia;
- Granados, Andrea;
- Glasner, Dustin;
- Han, Lucy;
- Truong, Kent;
- Akagi, Naomi;
- Nguyen, David;
- Neumann, Neil;
- Qazi, Daniel;
- Hsu, Elaine;
- Gu, Wei;
- Santos, Yale;
- Custer, Brian;
- Green, Valerie;
- Williamson, Phillip;
- Hills, Nancy;
- Lu, Chuanyi;
- Whitman, Jeffrey;
- Stramer, Susan;
- Wang, Candace;
- Reyes, Kevin;
- Hakim, Jill;
- Sujishi, Kirk;
- Alazzeh, Fariba;
- Pharm, Lori;
- Oon, Ching-Ying;
- Miller, Steve;
- Kurtz, Theodore;
- Hackett, John;
- Simmons, Graham;
- Busch, Michael;
- Chiu, Charles
We report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seropositivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors. We additionally describe the longitudinal dynamics of immunoglobulin-G, immunoglobulin-M, and in vitro neutralizing antibody titers in COVID-19 patients. Neutralizing antibodies rise in tandem with immunoglobulin levels following symptom onset, exhibiting median time to seroconversion within one day of each other, and there is >93% positive percent agreement between detection of immunoglobulin-G and neutralizing titers.
